SCHEMBL4705653

SCHEMBL4705653

c1ccc(Cn2cc(-c3nnnn3-c3ccccc3)nn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.59
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 7/20 0.48
LMNA P02545 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TSHR P16473 1/20 0.48
TEK Q02763 2/20 0.48
EPHB4 P54760 1/20 0.48
HTT P42858 1/20 0.48
GSK3B P49841 2/20 0.47
FLT3 P36888 1/20 0.47
KDR P35968 1/20 0.47
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.45
CASP3 P42574 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22510634 0.79 CYP19A1 (0.82) CYP19A1NPC1RAB9AALDH1A1LMNA
SCHEMBL15836586 0.75 CYP19A1 (0.93) CYP19A1NPC1RAB9ATEKEPHB4
SCHEMBL935182 0.75 CYP19A1 (1.00) CYP19A1NPC1RAB9ATEKEPHB4
SCHEMBL11536760 0.74 ALDH1A1 (0.65) ALDH1A1LMNASMN1; SMN2TSHRHTT
SCHEMBL12535881 0.72 NPC1 (0.88) CYP19A1NPC1RAB9ATEKEPHB4
SCHEMBL28907313 0.72 CYP19A1 (0.64) CYP19A1NPC1RAB9AALDH1A1LMNA
SCHEMBL12022166 0.71 CYP19A1 (0.84) CYP19A1NPC1RAB9ATEKEPHB4
SCHEMBL13880393 0.71 CYP19A1 (0.62) CYP19A1NPC1RAB9AALDH1A1LMNA
SCHEMBL2190292 0.70 CYP19A1 (0.66) CYP19A1NPC1RAB9ATEKGSK3B
SCHEMBL29275462 0.70 CYP19A1 (0.66) CYP19A1NPC1RAB9ATEKEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP claimed
CN-1312136-C Triazole derivatives as tachykinin receptor antagonists LILLY CO ELI (US) 2007-04-25 CN claimed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 US claimed
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 CYP19A1 2876/4885NPC1 563/4885RAB9A 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.